CG Oncology (NASDAQ:CGON) Hits New 1-Year High – Should You Buy?

CG Oncology, Inc. (NASDAQ:CGON) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $77.49 and last traded at $76.9830, with a volume of 20157 shares trading hands. The stock had previously closed at $76.56.

Wall Street Analyst Weigh In

CGON has been the subject of several analyst reports. Wall Street Zen lowered CG Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Piper Sandler increased their target price on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Wolfe Research assumed coverage on shares of CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $83.18.

CG Oncology Stock Performance

The firm has a market capitalization of $6.82 billion, a price-to-earnings ratio of -28.62 and a beta of 0.23. The company has a fifty day moving average of $68.35 and a two-hundred day moving average of $64.46.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. Equities analysts forecast that CG Oncology, Inc. will post -3.25 EPS for the current year.

Insider Activity

In related news, Director Brian Guan-Chyun Liu purchased 371,085 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the completion of the purchase, the director owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This represents a 24.49% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Mulay sold 24,165 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the sale, the director directly owned 24,165 shares in the company, valued at $1,816,241.40. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 37,129 shares of company stock worth $2,663,817. Corporate insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

Several large investors have recently modified their holdings of the stock. Whittier Trust Co. of Nevada Inc. acquired a new position in CG Oncology during the fourth quarter valued at approximately $27,000. NFSG Corp acquired a new stake in shares of CG Oncology in the 1st quarter valued at $34,000. Comerica Bank increased its stake in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the last quarter. Fifth Third Bancorp bought a new position in shares of CG Oncology in the 1st quarter valued at $74,000. Finally, KBC Group NV acquired a new position in shares of CG Oncology during the 1st quarter worth $78,000. 26.56% of the stock is owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.